“ My work with companies across the biopharmaceutical, medical device, diagnostic, instrumentation, and life sciences areas continues to inspire me as I help them raise the funding necessary to create therapies and solutions for major medical needs.
Michael specializes in corporate and securities law. He possesses more than 30 years of experience providing general corporate representation to public and private biopharmaceutical, medical device, diagnostic, instrumentation, and life sciences companies. He applies his broad experience in venture capital financings, public offerings, mergers and acquisitions, strategic alliances, technology licensing, and corporate spin-out transactions to each engagement.
Michael has undertaken over 300 venture capital financings raising an estimated $50 billion for his clients, recently assisting Auris Health raise over $650 million in financings prior to its sale to J&J for up to $5.75 billion.
He also brings extensive experience with negotiating strategic alliances, representing clients in major collaborations with GSK, Amgen, Schering-Plough, J&J, Daiichi, Astellas, and King Pharmaceuticals, and most recently with Pfizer, Merck, Baxter, Eisai, and Dainippon Sumitomo Pharma Co., Ltd.
Michael was the lead lawyer on the initial public offerings for companies such as Illumina, Neurocrine Biosciences, Cytokinetics, Pain Therapeutics, NeurogesX, Sequana Therapeutics, Ciphergen Biosystems, Argonaut Technologies, and Microcide Pharmaceuticals.
Michael was also the lead lawyer responsible for negotiating a number of notable biopharmaceutical spin-outs, including Onyx Pharmaceuticals (Chiron-Cetus), Tularik (Genentech), X-Ceptor (Ligand Pharmaceuticals), Metabasis (Gensia Sicor), and as well on the reverse merger of Transcept Pharmaceuticals with Novacea, creating a new publicly traded entity.
Michael is a frequent speaker on current venture capital climate, alternative financing techniques, strategic partnerships, and corporate governance topics.
LMG Life Sciences 2016
Legal 500 US 2016